The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
We are pleased that our recently announced positive data from the first stage of our Phase 2 SCOPE trial has been selected for poster presentation at SITC. Better treatment outcomes are needed for patients with advanced melanoma and these highly impressive early results for SCIB1 combined with doublet CPI therapy demonstrate a meaningful improvement. The SCOPE trial is on track to complete recruitment by the end of 2023 with data available in H1 2024. We look forward to sharing more on these encouraging results at SITC and how this could make a significant impact on melanoma patient survival."
Hi Mayo.
I think you are mixing two different factors (Cash Balance and Operating Loss) which may be confusing things. If we just look at Cash Balance, that was £28.7m at end of April 2022 dropping to £19.9m at end of April 23. This would suggest an annual cash burn of £8.8m but there is of course the £5.3m Genmab upfront payment during the period too, making it a total annual cash burn of £14.1m - or £1.175m per month. Looking ahead - and with Covidity now on the shelf - I would expect the monthly burn to drop closer to £1m. So if we had £19.9m in cash at April 30th, that's effectively 20 months which would see us right through next year and (just) into 2025. This is a prudent forecast though, as it doesn't take into account any additional deals or other 'left field' events.
AIMHO - and good luck all!
I think it's a typo, Burble, and should read 2039. This is taken from the July update RNS:
"iSCIB1+ has a number of competitive advantages, with potentially increased potency due to modifications to the product using Scancell's propriety AvidiMab® platform, and an extended patent life to 2039. iSCIB1+ is able to be used by a broader patient population because it incorporates more melanoma-specific epitopes."
It looks like audit delays are pretty common and UNLESS there are material difficulties, an initial dip is followed by a bounce:
"Halfords shares dropped 7% yesterday to 185p following the notice but bumped back up to 195p this afternoon"
BDO has form on this...and more than once...
https://www.cityam.com/tetrosyl-seeks-1m-in-compensation-from-bdo-over-9-month-audit-delay/
https://www.retailgazette.co.uk/blog/2023/06/halfords-auditor-extends/
https://viconsortium.com/vi-business/virgin-islands-audit-delays-frustrate-matching-fund-special-purpose-board-as-bdo-falls-behind
Hi WTP.
In the immediate future, it's the World Vaccine Congress in Barcelona (16th - 19th October) then a short hop to Madrid for ESMO (20th - 24th). Then back to Blighty for the Investors presentations on 24th.
Looks almost planned...!
Opens today in Barcelona. Lindy speaking on Thursday.
https://www.terrapinn.com/conference/world-vaccine-congress-europe/speaker-lindy-DURRANT.stm
Good luck Lindy - and good luck all!
Look what can happen when the right results drop...!
https://fortune.com/2023/10/13/tempest-therapeutics-shares-surge-after-roche-led-cancer-treatment-trial/
Here you go...
https://www.lsegissuerservices.com/spark/ScancellHoldings/events/ab1023d6-85fa-4125-be9f-527b5166fd7d
Hi TF.
Not sure if it is on the SCLP site yet, but you can watch the recording here:
https://www.lsegissuerservices.com/spark/ScancellHoldings/events/ab1023d6-85fa-4125-be9f-527b5166fd7d
You just need to provide name, email and company and you're in. A good reminder of just how good the science is.
Here's to another good day!
C
Https://www.linkedin.com/posts/mandeep-bhamrah_immunotherapy-cancervaccines-immunooncology-activity-7109809196518252544-hQ1h
Go on...give her a Like!
Scancell have just posted this on their LinkedIn company page. Those of you with Linkedin accounts may wish to click 'repost' to help spread the word among the wider business community...
https://www.linkedin.com/posts/scancell-limited_immunotherapy-cancervaccines-immunooncology-activity-7109800443832086528-yvqw
Good luck all!